For patients with advanced solid tumors harboring specific genetic alterations, the first-in-class synthetic lethal combination of WEE1 inhibitor zedoresertib plus PKMYT1 inhibitor lunresertib demonstrated promising antitumor activity and was generally well-tolerated, according to Phase I MYTHIC trial data reported by researchers at The University of Texas MD Anderson Cancer Center.
The Verdict
ClassificationLikely AI
ConfidenceHigh confidence
Analyzedtext, image
ImageAI Generated
Community Verdict
Sign in to vote
Be the first to vote on this assessment.
Embed Badge
Add this badge to your site to show the AI classification for this content.
[](https://real.press/content/72978040-68fe-4913-bcbd-f364c3e48a30)